Other Clinical Trial - 3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Status Terminated

Clinical Trial Summary

This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively measure tissue structural, functional, cellular, and molecular properties, providing a more robust, clinically relevant method for assessing cancer response to therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
Localized Resectable Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Stage A Adult Primary Liver Cancer (BCLC)
Stage B Adult Primary Liver Cancer (BCLC)

Clinical Trial Details

NCT number	NCT02057874
Study type	Interventional
Source	Vanderbilt-Ingram Cancer Center
Contact
Status	Terminated
Phase	N/A
Start date	February 2014
Completion date	December 4, 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00787787` - Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer	Phase 2
Completed	`NCT00052364` - Oxaliplatin in Treating Patients With Liver Cancer	Phase 2
Completed	`NCT01229111` - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers	Phase 2
Completed	`NCT00107536` - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	Phase 2
Completed	`NCT02072356` - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery	Early Phase 1
Completed	`NCT00604721` - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Phase 2
Completed	`NCT00101036` - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00028496` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT01766219` - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery	Phase 1/Phase 2
Terminated	`NCT00427973` - AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer	Phase 2
Completed	`NCT00321594` - Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Phase 1/Phase 2
Terminated	`NCT00087191` - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer	N/A
Completed	`NCT00006016` - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery	Phase 2
Completed	`NCT01643499` - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies	Phase 1
Completed	`NCT00639509` - IMC-A12 in Treating Patients With Advanced Liver Cancer	Phase 2
Completed	`NCT00083226` - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	Phase 2
Completed	`NCT00033462` - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer	Phase 2
Completed	`NCT01666756` - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	Phase 1
Active, not recruiting	`NCT02119065` - Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Recruiting	`NCT02557503` - Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE	Phase 4